| scholarly article | Q13442814 |
| P2093 | author name string | Schwartz S | |
| Stuart CA | |||
| Brodows RG | |||
| Graf CJ | |||
| Robertson KE | |||
| Bastyr EJ 3rd | |||
| Zagar A | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| group psychotherapy | Q837393 | ||
| P304 | page(s) | 1236-1241 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. | |
| P478 | volume | 23 |
| Q51483637 | A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. |
| Q36416211 | Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities |
| Q84988224 | Adiponectin protects endothelial cells from the damages induced by the intermittent high level of glucose |
| Q36164723 | An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives |
| Q35579452 | Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus |
| Q51493788 | Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk. |
| Q44655631 | Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure |
| Q44633755 | Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes |
| Q34804238 | Considerations on blood glucose management in Type 2 diabetes mellitus |
| Q48932220 | Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring |
| Q50230933 | Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. |
| Q35703026 | Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations |
| Q37111783 | Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. |
| Q35812833 | Diabetes control and complications: the role of glycated haemoglobin, 25 years on. |
| Q34173849 | Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline |
| Q36049114 | Effect of nutritional counseling and long term isomaltulose based liquid formula (MHN-01) intake on metabolic syndrome. |
| Q36097412 | Effects of a Macro-Nutrient Preload on Type 2 Diabetic Patients |
| Q62479497 | Effects of lipase inhibition on gastric emptying and alcohol absorption in healthy subjects |
| Q45232457 | Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes |
| Q42911684 | Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion |
| Q80391784 | Effects of pioglitazone and insulin on tight glycaemic control assessed by the continuous glucose monitoring system : a monocentric, parallel-cohort study |
| Q33424665 | Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients |
| Q34579697 | Gastric emptying in diabetes: clinical significance and treatment. |
| Q44352936 | Glycaemic risk and contribution of post-prandial glucaemia to glycosylated haemoglobin (HbA 1c ) |
| Q34602000 | Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties |
| Q38050151 | Humalog (lispro) for type 2 diabetes |
| Q34327231 | Hyperglycemia and cardiovascular disease |
| Q28972240 | Improvement of Glucose Metabolism in Patients with Impaired Glucose Tolerance or Diabetes by Long-Term Administration of a Palatinose-Based Liquid Formula as a Part of Breakfast |
| Q44633758 | Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model |
| Q37885450 | Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis |
| Q34663249 | Individualizing insulin management. Three practical cases, rules for regimen adjustment |
| Q31150222 | Influence of smoking and diet on glycated haemoglobin and 'pre-diabetes' categorisation: a cross-sectional analysis |
| Q39886593 | Inhibitory activity of Euonymus alatus against alpha-glucosidase in vitro and in vivo |
| Q33848334 | Insulin analogs and glycosylated hemoglobin target of less than 7% in type 2 diabetes: a systematic review of randomized trials. |
| Q35087539 | Insulin analogues: new therapies for type 2 diabetes mellitus. |
| Q34982099 | Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus |
| Q36750094 | Insulin lispro: a review of its use in the management of diabetes mellitus |
| Q35183776 | Insulin lispro: a useful advance in insulin therapy |
| Q24246084 | Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus |
| Q34451782 | Insulin therapy in type 2 diabetes |
| Q73531395 | Insulin therapy in type 2 diabetes |
| Q41855774 | Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis |
| Q34453173 | Insulinotropic meglitinide analogues |
| Q93965554 | Introduction |
| Q27027047 | Is there a relationship between mean blood glucose and glycated hemoglobin? |
| Q38123793 | Is there evidence to support use of premixed or prandial insulin regimens in insulin-naive or previously insulin-treated type 2 diabetic patients? |
| Q89159597 | Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes |
| Q51865158 | Lower visual acuity predicts worse utility values among patients with type 2 diabetes. |
| Q24245352 | Meglitinide analogues for type 2 diabetes mellitus |
| Q24247885 | Meglitinide analogues for type 2 diabetes mellitus |
| Q37964744 | Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis |
| Q22250988 | Metformin and body weight |
| Q48053983 | Novel Insights into the Inhibitory Effect and Mechanism of Proanthocyanidins from Pyracantha fortuneana Fruit on α-Glucosidase. |
| Q35219428 | Nutrition therapy for diabetic gastroparesis |
| Q46675368 | Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial |
| Q33488897 | Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses |
| Q37199304 | Optimum management of type 2 diabetes--timely introduction, optimization and intensification of basal insulin |
| Q34592210 | Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes |
| Q34451776 | Oral therapies for diabetic hyperglycemia |
| Q36903737 | Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists. |
| Q44125697 | Patient perceptions of prandial oral therapy for type 2 diabetes |
| Q35911073 | Perception of clinicians and diabetic patients on the importance of postprandial glucose control and diabetes education status: a cross sectional survey |
| Q36506133 | Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control |
| Q35954506 | Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practice. |
| Q36269662 | Prandial hyperglycemia: is it important to track and treat? |
| Q46484900 | Predictive factors of glycemic control in patients with type 2 diabetes mellitus in primary health care |
| Q46883811 | Premixed insulin analogues for the treatment of diabetes mellitus |
| Q33808889 | Relation of fasting and postprandial and plasma glucose with hemoglobinA1c in diabetics |
| Q33871459 | Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. |
| Q35751679 | Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus |
| Q34385405 | Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24240522 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24244739 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q37724096 | Risk of postprandial insulin resistance: the liver/vagus rapport |
| Q48123214 | Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial. |
| Q35115556 | Should Postprandial Glucose Be Routinely Measured and Treated to a Particular Target? No! |
| Q34542859 | Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin |
| Q59809146 | The Timing of Activity after Eating Affects the Glycaemic Response of Healthy Adults: A Randomised Controlled Trial |
| Q90583668 | The effect of oral essential amino acids on incretin hormone production in youth and ageing |
| Q37321871 | The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. |
| Q35907234 | The use of bolus insulin and advancing insulin therapy in type 2 diabetes |
| Q37786051 | Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review |
| Q33869207 | Upper gastrointestinal function and glycemic control in diabetes mellitus |
Search more.